Efficacy and Safety of Budesonide and Formoterol in One Pressurized Metered-Dose Inhaler in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease

[1]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[2]  S. Senn,et al.  Bronchodilation of formoterol administered with budesonide: device and formulation effects. , 2008, Contemporary clinical trials.

[3]  D. Halpin.  Mortality in COPD: Inevitable or Preventable? Insights from the Cardiovascular Arena , 2008, COPD.

[4]  T. Seemungal,et al.  The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. , 2008, American journal of respiratory and critical care medicine.

[5]  E. R. Sutherland,et al.  Inhaled steroids and outcomes in COPD: progressing beyond FEV1. , 2007, Chest.

[6]  D. Postma,et al.  A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. , 2007, Chest.

[7]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[8]  C. Vogelmeier,et al.  Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[9]  C. Jenkins,et al.  Salmeterol/Fluticasone propionate and survival in chronic obstructive pulmonary disease:the TORCH trail. , 2007 .

[10]  K. Lohr,et al.  Efficacy and Safety of Inhaled Corticosteroids in Patients With COPD: A Systematic Review and Meta-Analysis of Health Outcomes , 2006, The Annals of Family Medicine.

[11]  P. Jones.  St. George's Respiratory Questionnaire: MCID , 2005, COPD.

[12]  N. Leidy,et al.  Bridging the Gap: Using Triangulation Methodology to Estimate Minimal Clinically Important Differences (MCIDs) , 2005, COPD.

[13]  P. Calverley,et al.  Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease , 2003, European Respiratory Journal.

[14]  P. Calverley,et al.  Respiratory failure in chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[15]  R. Pauwels,et al.  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.

[16]  S. Man,et al.  Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter? , 2003, European Respiratory Journal.

[17]  R. Sansores,et al.  Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[18]  N. Leidy,et al.  Evaluating symptoms in chronic obstructive pulmonary disease: validation of the Breathlessness, Cough and Sputum Scale. , 2003, Respiratory medicine.

[19]  T. Bengtsson,et al.  Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study , 2002, European Respiratory Journal.

[20]  J. Yates,et al.  Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[21]  N. Pride,et al.  Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice , 2002, European Respiratory Journal.

[22]  Abdullah Alsaeedi,et al.  The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. , 2002, The American journal of medicine.

[23]  M. Decramer,et al.  Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial , 2002, European Respiratory Journal.

[24]  R. Dahl,et al.  Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[25]  J. Tu,et al.  Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[26]  R. Zuwallack,et al.  Use of a Long-acting Inhaled β2-Adrenergic Agonist, Salmeterol Xinafoate, in Patients with Chronic Obstructive Pulmonary Disease , 2001 .

[27]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[28]  S. Yancey,et al.  Efficacy of salmeterol xinafoate in the treatment of COPD. , 1999, Chest.

[29]  M. Becklake,et al.  Relationship between chronic dyspnea and expiratory flow limitation in patients with chronic obstructive pulmonary disease. , 1996, American journal of respiratory and critical care medicine.

[30]  John L. Hankinson,et al.  Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[31]  P. Jones,et al.  A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. , 1992, The American review of respiratory disease.

[32]  P. Jones,et al.  The St George's Respiratory Questionnaire. , 1991, Respiratory medicine.

[33]  W. Beninati,et al.  Air travel in patients with chronic obstructive pulmonary disease. , 1991, Archives of internal medicine.

[34]  J. Hankinson,et al.  Standardization of spirometry. , 1988, The American review of respiratory disease.

[35]  R M Gardner,et al.  Reference spirometric values using techniques and equipment that meet ATS recommendations. , 2015, The American review of respiratory disease.

[36]  D. Sin,et al.  Inhaled Corticosteroids and the Risk of Mortality and Readmission In Elderly Patients with Chronic Obstructive Pulmonary Disease , 2022 .